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Summary
AIM OF THE STUDY: Preeclampsia (PE) is associated
with severe maternal and fetal morbidity in the acute pre-
sentation and there is increasing evidence that it is also an
important risk factor for cardiovascular disease later in life.
Therefore, preventive strategies are of utmost importance.
The Fetal Medicine Foundation (FMF) London recently de-
veloped a first trimester screening algorithm for placenta-
related pregnancy complications, in particular early onset
preeclampsia (eoPE) requiring delivery before 34 weeks,
and preterm small for gestational age (pSGA), with a birth
weight <5th percentile and delivery before 37 weeks of
gestation, based on maternal history and characteristics,
and biochemical and biophysical parameters. The aim of
this study was to test the performance of this algorithm
in our setting and to perform an external validation of the
screening algorithm.
MATERIAL AND METHODS: Between September 2013
and April 2016, all consecutive women with singleton
pregnancies who agreed to this screening were included
in the study. The proposed cut-offs of ≥1:200 for eoPE,
and ≥1:150 for pSGA were applied. Risk calculations were
performed with Viewpoint® program (GE, Mountainview,
CA, USA) and statistical analysis with GraphPad version
5.0 for Windows.
RESULTS: 1372 women agreed to PE screening; the 1129
with complete data and a live birth were included in this
study. Nineteen (1.68%) developed PE: 14 (1.24%) at
term (tPE) and 5 (0.44%) preterm (pPE, <37 weeks), in-
cluding 2 (0.18%) with eoPE. Overall, 97/1129 (8.6%)
screened positive for eoPE, including both pregnancies
that resulted in eoPE and 4/5 (80%) that resulted in pPE.
Forty-nine of 1110 (4.41%) pregnancies without PE result-
ed in SGA, 3 (0.27%) of them in pSGA. A total of 210/1110
(18.9%) non-PE pregnancies screened positive for pSGA,
including 2/3 (66.7%) of the pSGA deliveries and 18/46
(39.1%) of term SGA infants.
CONCLUSION: Our results show that first trimester PE
screening in our population performs well and according
to expectations, whereas screening for SGA is associated
with a high false positive rate.
Key words: preeclampsia, screening, small for gestation-
al age, first trimester
Introduction
Preeclampsia (PE) affects 2 to 3% of all pregnancies and is
a major cause of maternal and fetal morbidity and mortal-
ity worldwide [1–3]. Similarly, being small for gestation-
al age (SGA), defined as birth weight below the fifth per-
centile, even without PE is also a major cause of adverse
outcome [4, 5]. Besides the immediate risk to mother and
child, there is rising evidence that these placenta-related
pregnancy complications are a major cardiovascular risk
factor for both in later life [6, 7]. Indeed, previous PE has
now been accepted as an additional risk factor for future
cardiovascular complications besides nicotine, obesity, di-
abetes and family history for cardiovascular disease [8, 9].
There is increasing evidence that it also poses a risk for
cognitive impairment in later life [10].
Several large studies and meta-analyses have demonstrat-
ed, that the use of low-dose aspirin (LDA) started early
during pregnancy in high-risk pregnancies reduces sub-
stantially the risk of PE and SGA [11, 12]. Traditionally,
high-risk pregnancies have been defined by obstetrical his-
tory and/or pre-existing maternal factors. The UK National
Institute for Health and Care Excellence (NICE) defines
women to be at high risk when at least one major risk fac-
tor (previous PE, chronic hypertension, pre-existing kid-
ney disease or diabetes, systemic lupus erythematosus
[SLE] or antiphospholipid syndrome [APS]) or two or
more minor risk factors (primiparity or interpregnancy in-
terval >10 years, body mass index [BMI] >35kg/m2, ma-
ternal age >40 years or family history of PE) are present
[13]. The American College of Obstetrics and Gynecology
(ACOG) does not distinguish between major and minor
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risk factors and requires only one anamnestic risk factor
(primiparity, previous PE, chronic hypertension, chronic
kidney disease, thrombophilia, in-vitro fertilisation [IVF],
family history of PE, pre-existing diabetes, obesity, SLE,
maternal age >40 years) to consider the pregnancy to be
at risk; they recommend prophylactic LDA only for very
high-risk pregnancies with a history of early onset
preeclampsia (eoPE) or repeated previous PE [14]. How-
ever, such screening strategies either consider a majority of
women to be at risk, or, at a reasonable false-positive rate
of about 10%, identify barely half of all women at risk for
PE [15] and even fewer of those at risk for SGA [16]. To
address this problem, studies have been conducted to better
characterise “at risk women” using in addition biochem-
ical and biophysical parameters to develop screening al-
gorithms mainly for the first trimester [15–19]. With their
aid, detection rates of up to 96% for eoPE and about 75%
for preterm preeclampsia (pPE), as well as for preterm
delivery of an SGA infant (pSGA) have been published
[15, 16]. The ASPRE (ASpirin for the evidence-based
PREeclampsia prevention) trial recently demonstrated the
efficacy of LDA in preventing PE in women defined as
“at risk” for PE on the basis of a combined first trimester
screening algorithm [20].
Since 2013, we have offered PE and SGA screening to
all women with singleton pregnancies, using the algorithm
provided by the Fetal Medicine Foundation (FMF) Lon-
don. The aim of this study was to assess the performance
of these screening algorithms in our population.
Material and methods
This was a cross-sectional study of all women who were
seen at our outpatient clinic for their pregnancy between
September 2013 and April 2016 and who opted to have
screening for PE at their 11- to 14-weeks ultrasound scan.
The outpatient clinic is part of our department of obstetrics
and gynaecology and has roughly 8000 consultations per
year, taking care of around 2000 pregnancies. We use the
algorithm provided by the FMF London, which combines
the background risk defined by maternal history and char-
acteristics with the mean arterial pressure (MAP), the mean
pulsatility index (PI) of both uterine arteries (UtA), and the
values of the biochemical and angiogenetic markers preg-
nancy-associated plasma protein A (PAPP-A) and placen-
tal growth factor (PlGF). According to the Bayes theorem,
the likelihood ratios of each independent parameter are
multiplied with the background risk to calculate an individ-
ual risk [15, 17, 18, 21, 22]. As PAPP-A did not improve
the sensitivity of the screening algorithm, we did not con-
sider it a mandatory variable in our study [15]. The blood
pressure was assessed by using a pregnancy-validated de-
vice (UEBE Visomat comfort) twice on both arms at the
end of the ultrasound scan; the software provided by View-
point Version 5.6.25.284 (GE, Mountainview, CA, USA)
calculated the MAP of the four measurements. The UtA
PI was measured by certified scanners according to the
guidelines of the FMF London. PlGF and PAPP-A were
measured on Kryptor Compact Plus from Brahms GmbH.
Blood was drawn for PAPP-A measurement at the first an-
tenatal visit, between 8 and 14 weeks of gestation, and for
PlGF between 10 and 14 weeks of gestation. Whenever
PlGF was available between 11 and 14 weeks, we used that
result; however, as we recently showed, PlGF differenti-
ates preeclamptic from normal pregnancies from 10 weeks
of gestation onward, so we included PlGF values between
10+0 and 10+6 weeks of gestation when no other measure-
ment was available [23]. Multiple of the medians (MoMs)
of all parameters were calculated with the use of View-
point. The risk for PE requiring delivery before 34 weeks,
37 weeks and at term, and the risk of SGA requiring deliv-
ery before 37 weeks were also calculated by the Viewpoint
software. The proposed cut-offs of ≥1:200 for eoPE, and
≥1:150 for pSGA were applied [18]. For comparative pur-
poses we retrospectively analysed the data also according
to the screening criteria of NICE and ACOG [13, 14].
Usually we recommend LDA 100 mg to women with pre-
vious PE and/or SGA pregnancies, chronic hypertension,
pre-existing diabetes, SLE, APS and/or chronic kidney dis-
ease [13]. From 2013 onward we also included as indica-
tion for LDA prophylaxis a risk score of ≥1:200 for eoPE
based on the FMF London first trimester risk stratification
tool [15, 18, 24].
PE was defined according to the criteria established by
the International Society for the Study of Hypertension in
Pregnancy (ISSHP), systolic blood pressure of 140 mm Hg
or more and/or diastolic blood pressure of 90 mm Hg or
more either pre-existing or developing after 20 weeks of
gestation in a previously normotensive women, together
with significant proteinuria (300 mg/24-h urine collection,
or 30 mg proteins / mmol creatinine, or ++ on dip-stick
testing) and/or other signs of maternal endothelial dys-
function and/or uteroplacental dysfunction with intrauter-
ine growth restriction [25]. SGA was defined as birth
weight below the fifth percentile according to the FMF
screening algorithm [18]. The study was approved by the
Ethics Committee of the University of Bern.
Statistical analyses were performed with GraphPad version
5.0 for Windows (GraphPad Software, San Diego, CA).
Spearman rank correlation and linear regression were used
to analyse the correlation between the individual markers
and gestational age. Continuous variables were analysed
with the Student t-test or Mann-Whitney U-test, and pro-
portions were evaluated with use of the Fisher’s exact test
or chi-squared test. Statistical significance was considered
to be achieved when p was less than 0.05.
Results
During the study period, 1372 patients with singleton preg-
nancies agreed to undergo screening; in 1209 (88%) of
them, complete screening including maternal history and
characteristics, MAP, UtA-PI and PlGF was performed.
In 163 patients some screening parameters were missing,
mostly PlGF as initially we did not have the possibility to
measure it, and they were excluded from further analysis.
In 1136 of 1209 (94%), PAPP-A was also assessed.
Pregnancy outcome parameters were available for 1150 of
the 1209 (95.1%) cases. Of those, 16 (1.4%) pregnancies
resulted in a second trimester miscarriage, 5 (0.4%) were
terminated or an intrauterine fetal death was diagnosed
(none related to PE). A total of 1129 (98.2%) resulted in a
live birth and were used for further analyses.
Nineteen of 1129 (1.68%) women developed PE, 5
(0.44%) of them pPE, including 2 (0.18%) with eoPE and
14 (1.24%) with PE at term. Forty-nine of the 1110
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(4.41%) pregnancies without PE were SGA and 3 (0.27%)
of those required preterm delivery. The remaining 1061
(92.3%) pregnancies were delivered without preeclampsia
and with a newborn with a weight above the fifth per-
centile; these are henceforth referred to as controls. Pa-
tients’ characteristics and pregnancy outcomes are shown
in table 1. Table 2 compares our population with that used
by the FMF London to develop and validate the screening
algorithm [15, 17].
Performance of individual screening parameters
The median (IQR) absolute values and MoMs of all indi-
vidual parameters in controls compared with preterm and
term PE and SGA are depicted in table 3 and figure 1.
Mean arterial pressure
No correlation was found between MAP or MAP-MoMs
with gestational age between 11 and 14 weeks gestation in
uneventful pregnancies nor in pregnancies complicated by
PE or SGA.
Uterine artery pulsatility index
UtA PI significantly decreased between 11 and 14 weeks
(p >0.0001, r = ˗0.113) in controls, whereas UtA PI-MoMs
remained stable. There was no correlation with gestational
age of UtA PIs or their MoMs in PE or SGA.
The median UtA PI-MoM was 0.93 (IQR 0.76–1.15) in un-
eventful pregnancies and therefore somewhat lower than
expected, but still in the range, whereas the mean ± stan-
dard deviation UtA PI was 0.97 ± 0.30 and therefore as ex-
pected. We performed a sub-analysis of a random sample
of 95 measurements. Only 41 (43.2%) measurements ful-
filled all criteria requested by the FMF London, whereas
32 (33.7%) had an angle correction of more than 30° or the
sample gate was not 2 mm, and in 22 (23.2%) the mea-
sured blood flow velocity was less than 60 cm/s. To assess
retrospectively whether the measurement was taken at the
height of internal cervical os is difficult. In the 41 measure-
ments that fulfilled all FMF criteria and in the 73 that had a
correct blood flow velocity, the median UtA PI MoM was
1.014 (IQR 0.87–1.27) and 1.009 (0.83–1.31) , respective-
ly, (p = 0.99).
Table 1: Patients’ characteristics and pregnancy outcome of our study population divided into uneventful pregnancies (controls), pregnancies that developed preeclampsia and
pregnancies that resulted in a small for gestational age infant (<5th percentile).
Controls
(n = 1061)
PE
(n = 19)
SGA
(n = 49)
Maternal age (years), median (IQR) 31.0 (27.0–35.0) 32.0 (28.0–34.0) 32.0 (28.5–35.5)
Maternal weight (kg), median (IQR) 63.0 (56.0–71.6) 67.0 (61.0–77.5) 57 (51.6–65.9)*
Maternal height (cm), median (IQR) 165 (160–170) 164 (160–168) 162 (158–165)*
Maternal BMI at 12 weeks (kg/m2), median (IQR 22.8 (20.7–26.2) 24.6 (22.9–31.1)* 21.6 (19.4–25.7)
Fetal CRL (mm), median (IQR) 64.9 (59.6–70.8) 62.7 (56.1–67.0) 65.4 (60.1–69.4)
Gestational age (weeks), median (IQR) 12.7 (12.3–13.1) 12.4 (12.0–12.7) 12.7 (12.3–13.0)
Ethnicity, n (%):
Caucasian 779 (73.4) 14 (73.7) 37 (75.5)
Black 153 (14.4) 3 (15.8) 5 (10.2)
South Asian 55 (4.9) 1 (5.3) 3 (6.1)
East Asian 46 (4.3) 1 (5.3) 3 (6.1)
Mixed 28 (2.6) 0 (0) 1 (2.0)
Parity, n (%):
Nulliparous 535 (50.4) 14 (73.7) 28 (57.1)
Parous without previous PE or SGA 467 (44.0) 4 (21.1) 15 (30.6)
Parous with previous PE 21 (2.0) 0 (0) 5 (10.2)*
Parous with previous SGA 32 (3.0) 0 (0) 1 (2.0)
Parous with previous PE and SGA 6 (0.6) 1 (5.3) 0 (0)
Cigarette smoker, n (%) 88 (8.3) 0 (0) 9 (18.4)*
Family history of PE, n (%) 13 (1.2) 0 (0) 0 (0)
Mode of conception, n (%):
Spontaneous 973 (91.7) 18 (94.7) 43 (87.8)
ART 88 (8.3) 1 (5.3) 6 (12.2)
Chronic hypertension, n (%) 16 (1.5) 3 (15.8)* 3 (6.1)*
Pre-existing diabetes mellitus, n (%) 6 (0.6) 1 (5.3) 1 (2)
SLE or APS, n (%) 6 (0.6) 0 (0) 0 (0)
Mode of delivery, n (%):
Vaginal 565 (53.3) 2 (10.5)* 19 (38.8)
Operative vaginal delivery 125 (11.8) 2 (10.5) 1 (2.0)*
Caesarean section 371 (35.0) 15 (78.9)* 29 (59.2)*
Gestational age at delivery (weeks), median (IQR 39.6 (38.7–40.6) 38.7 (36.6–40.0)* 39.0 (38.1–39.8)*
Delivery before 37 weeks, n (%) 50 (4.7) 5 (26.3)* 3 (6.1)
Birth weight (kg), median (IQR) 3.37 (3.08–3.64) 3.06 (2.66–3.38)* 2.45 (2.31–2.62)*
Birth weight percentile, median (IQR) 45.0 (25.7–65.8) 24.8 (15.9–62.8) 2.6 (1.5–3.8)*
Birthweight <10th percentile, n (%) 65 (6.1) 4 (21.1)* 49 (100)*
Birthweight <5th percentile, n (%) 0 (0) 3 (15.8)* 49 (100)*
APS = antiphospholipid antibody syndrome ART = assisted reproductive technology; BMI = body mass index; CRL = crown rump length; IQR = interquartile range; PE =
preeclampsia; SGA = small for gestational age; SLE = systemic lupus erythematosus Comparisons between each outcome group and unaffected controls: Fisher’s exact test for
categorical variables and Mann-Whitney test for continuous variables. * p <0.05 (considered significant).
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Placental growth factor
PlGF increased significantly between 10 and 14 weeks of
gestation in uneventful pregnancies (p <0.0001, r = 0.31),
as well as in pregnancies resulting in SGA (p = 0.015, r =
0.35) but not with PE. PlGF-MoMs did not correlate with
gestational age in complicated and uncomplicated preg-
nancies.
Pregnancy-associated plasma protein A
PAPP-A increased significantly between 8 and 14 weeks of
gestation in uneventful pregnancies (p <0.0001, r = 0.75)
and also in pregnancies resulting in tPE (p = 0.0008, r
= 0.79) and SGA (p <0.0001, r = 0.68), but not in pPE.
No correlation with gestational age was found in PAPP-A-
MoMs in complicated and uneventful pregnancies.
Performance of screening
Preeclampsia screening algorithm
Ninety-seven of 1129 (8.6%) screening tests showed a risk
≥1:200 for eoPE, and in 121/1129 (10.7%) cases the risk
was ≥1:269 (the risk cut-off published by FMF at a false-
positive rate of 10% [15]). A total of 125/1129 (11.1%)
had a risk ≥1:67 for pPE and 131/1129 (11.6%) had a risk
≥1:12 for tPE (each risk cut-off according to FMF London
at a false-positive rate of 10% [15]). At a false-positive rate
of 10%, the risk cut-offs in our patient group were 1:260
for eoPE, 1:65 for pPE and 1:12 for tPE. Overall, 95.5% of
the patients at risk for eoPE also have an increased risk for
pPE.
Performance of preeclampsia screening
Both of the two patients (100%) with eoPE, as well as 4/
5 (80%) patients who developed pPE were screen positive
for eoPE, as well as pPE and tPE; 7 of 14 (50%) patients
Table 2: Comparison of our collective with the collectives used by the FMF London in the development [15] and validation [17] of the preeclampsia screening algorithm.
Population Bern
(n = 1129
Akolekar 2013 [15]
(n = 58 884)
O’Gorman 2016 [17]
(n = 35 948)
Maternal age (years), median (IQR) 31.0 (27.0–35.0) 32.0 31.3
Maternal weight (kg), median (IQR) 62.6 (56–71.3) 65.6 66.7
Maternal height (cm), median (IQR) 165 (160–170) n.a. 164.5
Maternal BMI at 12 weeks (kg/m2), median (IQR) 22.8 (20.6–26.2) n.a. 24.6
Fetal CRL (mm), median (IQR) 64.9 (59.6–70.6) 63.4 n.a.
Ethnicity, n (%):
White 830 (73.5) 43 265 (73.5) 25 879 (72.0)
Black 161 (14.3) 9793 (16.6)* 6681 (18.6)*
South Asian 59 (5.2) 2844 (4.8) 1623 (4.5)
East Asian 50 (4.4) 1489 (2.5)* 846 (2.4)*
Mixed 29 (2.6) 1493 (2.5) 919 (2.6)
Parity, n (%):
Nulliparous 577 (51.1) 29 108 (49.4) 17 361 (48.3)
Parous without previous PE 519 (46.0) 27 955 (47.5) 17 311 (48.2)
Parous with previous PE 33 (2.9) 1821 (3.1) 1276 (3.5)
Cigarette smoker, n (%) 97 (8.6) 4584 (7.8) 3263 (9.1)
Family history of PE, n (%) 13 (1.2) 2629 (4.5)* 1518 (4.2)*
Conception, n (%):
Spontaneous 1034 (91.6) 56 795 (96.3)* n.a.
ART 95 (8.4) 2179 (3.7)* n.a.
Chronic hypertension, n (%) 22 (1.9) 685 (1.2)* 561 (1.6)
Pre-existing diabetes mellitus, n (%) 8 (0.7) 411 (0.7) 325 (0.9)
SLE or APS, n (%) 6 (0.5) 125 (0.2) 53 (0.1)*
APS = antiphospholipid antibody syndrome ART = assisted reproductive technology; BMI = body mass index; CRL = crown rump length; IQR = interquartile range; n.a. = not
available; PE = preeclampsia; SLE = systemic lupus erythematosus Comparisons between each outcome group and unaffected controls: Fisher’s exact test for categorical vari-
ables and Mann-Whitney test for continuous variables. * p <0.05 (considered significant).
Table 3: Median and interquartile range of individual screening parameters and their multiple of the medians in uneventful pregnancies compared with preterm preeclampsia,
term preeclampsia and delivery of infant small for gestational age.
Controls
(n = 1061)
Preterm PE
(n = 5)
Term PE
(n = 14)
SGA
(n = 49)
MAP (mm Hg) 84.8 (80.4–89.8) 96.4 (89.1–104.6)* 94.1 (88.3–98.7)** 86.3 (79.4–91.5)
MAP-MoM 1.00 (0.95–1.06) 1.14 (1.02–1.16)* 1.10 (1.05–1.17)** 1.01 (0.96–1.07)
UtA PI 1.50 (1.21–1.85) 1.71 (1.60–2.45) 1.36 (1.13–1.88) 1.57 (1.30–2.01)
UtA PI-MoM 0.93 (0.76–1.15) 1.07 (0.96–1.55) 0.88 (0.72–1.16) 0.97 (0–79–1.27)
PlGF (pg/ml) 38.9 (29.9–52.9) 19.0 (17.3–31.3)** 32.6 (16.5–37.1)** 35.1 (25.6–56)
PlGF-MoM 0.99 (0.79–1.24) 0.74 (0.48–1.00) 0.68 (0.50–0.87)** 0.84 (0.69–1.14)*
PAPP-A (mU/l) 2.09 (1.04–3.94) 1.67 (0.40–1.83) 1.63 (0.72–4.32) 1.61 (0.81–3.55)
PAPP-A-MoM 1.02 (0.72–1.50) 0.75 (0.59–1.04) 0.75 (0.46–1.12)* 0.75 (0.57–1.20)**
MAP = mean arterial pressure; MOM = multiple of the medians; PAP-A = pregnancy-associated plasma protein A; PE = preeclampsia; PlGF = placental growth factor; SGA =
small for gestational age; UtA PI = uterine artery pulsatility index Comparison between controls and complicated pregnancies by Mann-Whitney U test. Significance level *p<0.05,
**p<0.005
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with tPE were screen positive for tPE, resulting overall in
11/19 (57.9%) PE pregnancies that were screen positive.
In comparison, only 5/19 (26.3%) of our PE patients but
99/1129 (8.8%) of the total collective would be considered
at risk according to the criteria adopted by NICE [13].
Thirty-one of 1129 pregnancies were screen positive ac-
cording to both FMF London and NICE; of note, none of
the 68 remaining women at risk according to NICE but
6/66 (9%) with positive first trimester screening only, de-
veloped PE (fig. 2). The negative predictive value of both
tests was excellent (98.6% and 99.2%, respectively); how-
ever, the absolute false negative results are 42.1% with
first trimester screening and 73.7% according to NICE (p
= 0.099). When we considered the recommendation pub-
lished by the ACOG [14], 730 (64.7%) of our cases would
have been defined as high risk for placental associated
pregnancy complications (fig. 2).
SGA screening algorithm and performance
Overall, 210/1110 (18.9%) screening tests in pregnancies
without PE showed a risk ≥1:150 for pSGA; at that cut-
off only 5% are expected to screen positive by the FMF
London [16]. Also, 8/19 (42.1%) pregnancies with PE
screened positive for SGA, including both pregnancies
with eoPE; however, none of the eight resulted in pSGA.
Only three pregnancies resulted in pSGA, two (66.7%) of
which screened positive.
Figure 1: Mean arterial pressure, uterine artery Doppler, placental growth factor (PlGF) and pregnancy-associated plasma protein A (PAPP-A)
and their multiple of the medians (MoMs) in uneventful and complicated pregnancies over the course of the first trimester.PE = preeclampsia;
SGA = small for gestational age
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Aspirin prescription
A total of 116 of the 1129 (10.3%) women were prescribed
low-dose aspirin: 90/97 women at risk for eoPE according
to first trimester screening and 52/99 women with risks
from maternal history including 30/31 women with risks
according to both screening modalities received LDA. An
additional four women were given LDA for other reasons.
We did not test compliance.
Discussion
Main findings of the study
This study confirmed that first trimester screening with
use of the FMF algorithm for preeclampsia performs well
and according to expectations in our mixed population [15,
17]. The validation of the screening algorithm in an in-
dependent population with analysis of the performance of
each screening parameter was the main strength of our
study. With the limited number of pregnancies requiring
preterm delivery due to SGA in our population, this study
is not powered to confirm that first trimester screening
for growth restriction performs accordingly [18]. Of note,
the incidence of PE in our population was remarkable low
compared with published data [1–3, 15, 19, 24]. This was
also one of the main limitations of our study. Compared
with the population studied by the FMF London, our pop-
ulation was characterised by a higher prevalence of assist-
ed reproduction technology (ART) pregnancies, and more
women with chronic hypertension (table 2). Maybe the al-
ready high sensibility to prescribing LDA in at risk situa-
tions in our clinic and our policy to widen the indication for
LDA prophylaxis to include also screen-positive women
led to this low incidence of PE [20, 24]. This hypothesis
fits well with results of another prospective Swiss study,
which described a prevalence of PE of 2.31%; unfortunate-
ly, no information was provided on the use of prophylac-
tic LDA in that study [26]. The recently published ASPRE
trial also demonstrated a significant reduction of pPE with
the use of LDA [20].
Performance of the algorithm in our cohort
Through intensive research in the last decade, many first
trimester markers for PE besides maternal history and
characteristics have been identified [15, 16, 27, 28]. With
the most valuable of those, various screening algorithms
have been developed [15, 17, 29] and are still being con-
stantly refined. The screening algorithm developed by the
FMF London is based on data of nearly 60 000 pregnancies
and demonstrates a significant improvement in the de-
tection rate for PE compared with screening by maternal
history alone [15]. The performance of the screening al-
gorithm has recently been validated; however, external in-
dependent validation was requested [17]. Our population,
even though much smaller, varies only slightly from the
population studied by the FMF London in terms of back-
ground risk. The most important risk factors for PE are
chronic hypertension, type I diabetes mellitus, SLE or APS
and chronic kidney disease. These pathologies are over-
represented in our cohort owing to referral of high-risk
women [21]. Additionally the prevalence of pregnancies
conceived by ART in our group was higher, maybe because
we work in close collaboration with our IVF clinic [21].
We have, however, fewer African-Caribbean women and
fewer cases with a positive family history for PE. The only
explanation we find for the low incidence of women with
a positive family history is the probably too low awareness
of the patients of that condition (table 2). Moreover, we
demonstrated that the biochemical and biophysical screen-
ing parameters used were in the expected range in uncom-
plicated pregnancies [15, 17]. Our rates of screen-positive
results were also very similar to those described by the
FMF London, and we reach almost identical cut-offs in the
different risk calculations at a false-positive rate of 10%
[15–18]. As we chose to treat women at risk for early on-
set PE with low-dose aspirin, we cannot directly comment
on the detection rate. However, assuming LDA prevented
or postponed some cases of PE, one would expect more of
the screen-positive women to develop PE, as mostly they
received low-dose aspirin, which would again increase the
detection rate.
Figure 2: Performance of preeclampsia (PE) screening in Bern by use of first trimester combined screening according to the Fetal Medicine
Foundation (FMF) London, compared with screening by anamnestic risk factors as proposed by the UK National Institute for Health and Care
Excellence (NICE) and American College of Obstetrics and Gynecology (ACOG).
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First trimester screening detects almost twice the number
of women who develop PE at almost the same false pos-
itive rate, as compared with the risk assessment proposed
by NICE [13], which is also in line with described detec-
tion rates [15] (fig. 2). The difference was not significant in
our study group because of the relatively small population
examined and, mostly, because of the low incidence of PE.
Risk stratification as proposed by ACOG results in a very
high false-positive rate and therefore does not meet the re-
quirements of a screening test.
Importance of training in uterine artery Doppler as-
sessment
The only parameter that did not perform exactly as expect-
ed was the UtA PI. Our sub-analysis of a random sample of
UtA PIs demonstrated the importance of precise measure-
ments. Decreased blood flow velocities in the sample par-
ticularly influence the results, as they imply that the wrong
vessel was chosen. However, the chosen samples in a sub-
analysis, even though randomly assigned, always are sub-
ject to bias, as they might not exactly represent the whole
studied population. Another important aspect is that the
measurement was not taken above the internal os, as there
the PI becomes lower [30]. This difficulty could eventually
be overcome if the UtA PI is measured in a transverse view
of the internal cervical os, as was recently proposed. Rid-
ding et al [31] demonstrated that regular feedback to indi-
vidual operators via cumulative sum (CUSUM) and target
charts improves measurement performance. As in our find-
ings, this emphasises the importance of training and regu-
lar quality controls, just as it is required for the assessment
of the nuchal translucency. This might have reduced our
screen-positive rate somewhat, but it needs to be empha-
sised that our results were still in the expected range.
Low-dose aspirin
Park et al. [24] demonstrated that LDA reduces the risk of
PE in screen positive patients. Our results suggest the same
and the ASPRE trial, a randomised placebo-controlled trial
that tested LDA in women who had a positive result in
the first trimester PE screening, confirmed these findings
recently [20]. Today, no evidence exists that prescribing
LDA to all pregnant women might further decrease the in-
cidence of PE [32], and whereas LDA seems to be safe
in pregnancies at risk, there is some evidence of increased
risk for placental abruption and gastrointestinal bleeding
[33, 34]. This risk might become more important if LDA
were prescribed universally. There is evidence that, ow-
ing to aspirin resistance, 150 mg rather than a lower dose
should be prescribed [20]. Our small study does not allow
any comment on that. However, the incidence of pPE in
our collective is in line with the incidence described by
Park et al. [24], who prescribed 150 mg aspirin.
Further implications of preventing preeclampsia
PE is an important risk factor for maternal cardiovascular
disease later in life [6, 8, 9] and there is evidence that im-
paired placental function results in fetal cardiac remodel-
ling, which in turn can also lead to cardiovascular disease
in adult life [35]. Although predisposing factors for later
cardiovascular disease may already exist prior to the onset
of PE and even increase the risk for PE, the vascular dam-
age caused by inflammatory stress, coagulation dysregula-
tion and endothelial damage during PE poses an additional
risk [36]. Prevention of placental disorders, besides the as-
pect of the immediate danger the diseases pose to mother
and child, should therefore be considered as a task of ut-
most importance to prevent future disease in the newborn
and mother. Identifying women at risk for PE and SGA and
installation of preventive measures must therefore be expe-
dited.
Disclosure statement
No financial support and no other potential conflict of interest relevant
to this article was reported
References
1 Knight M, Tuffnell D, Kenyon S, Shakespeare J, Gray R, Kurinczuk JJ,
eds. on behalf of MBRRACE-UK. Surveillance of maternal deaths in
the UK 2011–2013. Oxford: National Perinatal Epidemiology Unit, Uni-
versity of Oxford; 2015.
2 Manktelow BN, Smith LK, Seaton SE, Hyman-Taylor P, Kurinczuk JJ,
Field DJ, et al., on behalf of the MBRRACE-UK collaboration. MBR-
RACE-UK Perinatal Mortality Surveillance Report: UK Perinatal
Deaths for Births from January to December 2014. Leicester: The Infant
Mortality and Morbidity Studies, Department of Health Sciences, Uni-
versity of Leicester; 2016.
3 Duley L. The global impact of pre-eclampsia and eclampsia. Semin
Perinatol. 2009;33(3):130–7. doi: http://dx.doi.org/10.1053/j.sem-
peri.2009.02.010. PubMed.
4 Lawn JE, Blencowe H, Waiswa P, Amouzou A, Mathers C, Hogan D, et
al.; Lancet Ending Preventable Stillbirths Series study group; Lancet
Stillbirth Epidemiology investigator group. Stillbirths: rates, risk factors,
and acceleration towards 2030. Lancet. 2016;387(10018):587–603. doi:
http://dx.doi.org/10.1016/S0140-6736(15)00837-5. PubMed.
5 Lindqvist PG, Molin J. Does antenatal identification of small-for-gesta-
tional age fetuses significantly improve their outcome? Ultrasound Ob-
stet Gynecol. 2005;25(3):258–64. doi: http://dx.doi.org/10.1002/
uog.1806. PubMed.
6 Ghossein-Doha C, van Neer J, Wissink B, Breetveld N, de Windt LJ,
van Dijk AP, et al. Pre-eclampsia, an important female specific risk fac-
tor for asymptomatic heart failure. Ultrasound Obstet Gynecol.
2017;49(1):143–9.
7 Sehgal A, Skilton MR, Crispi F. Human fetal growth restriction: a car-
diovascular journey through to adolescence. J Dev Orig Health Dis.
2016;7(6):626–35. doi: http://dx.doi.org/10.1017/S2040174416000337.
PubMed.
8 Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones
DM, et al. Effectiveness-based guidelines for the prevention of cardio-
vascular disease in women--2011 update: a guideline from the american
heart association. Circulation. 2011;123(11):1243–62. doi:
http://dx.doi.org/10.1161/CIR.0b013e31820faaf8. PubMed.
9 Wu P, Haththotuwa R, Kwok CS, Babu A, Kotronias RA, Rushton C, et
al. Preeclampsia and future cardiovascular health: a systematic review
and meta-analysis. Circ Cardiovasc Qual Outcomes.
2017;10(2):e003497; epub ahead of print. doi: http://dx.doi.org/10.1161/
CIRCOUTCOMES.116.003497. PubMed.
10 Fields JA, Garovic VD, Mielke MM, Kantarci K, Jayachandran M,
White WM, et al. Preeclampsia and cognitive impairment later in life.
Am J Obstet Gynecol. 2017;217(1):74.e1–11; epub ahead of print. doi:
http://dx.doi.org/10.1016/j.ajog.2017.03.008. PubMed.
11 Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, et
al. Prevention of preeclampsia and intrauterine growth restriction with
aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol.
2010;116(2 Pt 1):402–14. doi: http://dx.doi.org/10.1097/
AOG.0b013e3181e9322a. PubMed.
12 Roberge S, Nicolaides KH, Demers S, Villa P, Bujold E. Prevention of
perinatal death and adverse perinatal outcome using low-dose aspirin: a
meta-analysis. Ultrasound Obstet Gynecol. 2013;41(5):491–9. doi:
http://dx.doi.org/10.1002/uog.12421. PubMed.
13 National Institute of Health and Care Excellence. Hypertension in preg-
nancy: diagnosis and management. Clinical Guideline CG107. 2011.
Available from: https://www.nice.org.uk/guidance/cg107.
14 Task Force on Hypertension in Pregnancy. Hypertension in Pregnancy.
Washington, DC: American College of Obstetricians and Gynecologists;
2013.
15 Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH. Compet-
ing risks model in early screening for preeclampsia by biophysical and
Original article Swiss Med Wkly. 2017;147:w14498
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 7 of 8
biochemical markers. Fetal Diagn Ther. 2013;33(1):8–15. doi:
http://dx.doi.org/10.1159/000341264. PubMed.
16 Karagiannis G, Akolekar R, Sarquis R, Wright D, Nicolaides KH. Pre-
diction of small-for-gestation neonates from biophysical and biochemi-
cal markers at 11-13 weeks. Fetal Diagn Ther. 2011;29(2):148–54. doi:
http://dx.doi.org/10.1159/000321694. PubMed.
17 O’Gorman N, Wright D, Syngelaki A, Akolekar R, Wright A, Poon LC,
et al. Competing risks model in screening for preeclampsia by maternal
factors and biomarkers at 11-13 weeks gestation. Am J Obstet Gynecol.
2016;214(1):103.e1–12. doi: http://dx.doi.org/10.1016/
j.ajog.2015.08.034. PubMed.
18 Poon LC, Syngelaki A, Akolekar R, Lai J, Nicolaides KH. Combined
screening for preeclampsia and small for gestational age at 11-13 weeks.
Fetal Diagn Ther. 2013;33(1):16–27. doi: http://dx.doi.org/10.1159/
000341712. PubMed.
19 Crovetto F, Figueras F, Triunfo S, Crispi F, Rodriguez-Sureda V,
Dominguez C, et al. First trimester screening for early and late
preeclampsia based on maternal characteristics, biophysical parameters,
and angiogenic factors. Prenat Diagn. 2015;35(2):183–91. doi:
http://dx.doi.org/10.1002/pd.4519. PubMed.
20 Rolnik DL, Wright D, Poon LC, O’Gorman N, Syngelaki A, de Paco
Matallana C, et al. Aspirin versus placebo in pregnancies at high risk for
preterm preeclampsia. N Engl J Med. 2017;NEJMoa1704559; epub
ahead of print. doi: http://dx.doi.org/10.1056/NEJMoa1704559.
PubMed.
21 Wright D, Akolekar R, Syngelaki A, Poon LCY, Nicolaides KH. A com-
peting risks model in early screening for preeclampsia. Fetal Diagn
Ther. 2012;32(3):171–8. doi: http://dx.doi.org/10.1159/000338470.
PubMed.
22 The Fetal Medicine Foundation. Assessment of risk for preeclampsia.
Clinical algorithm. Available from: www.fetalmedicine.org/research/as-
sess/preeclampsia
23 Mosimann B, Amylidi-Mohr S, Höland K, Surbek D, Risch L, Raio L.
Importance of Timing First-Trimester Placental Growth Factor and Use
of Serial First-Trimester Placental Growth Factor Measurements in
Screening for Preeclampsia. Fetal Diagn Ther. 2017; epub ahead of
print. doi: http://dx.doi.org/10.1159/000455946.
24 Park F, Russo K, Williams P, Pelosi M, Puddephatt R, Walter M, et al.
Prediction and prevention of early-onset pre-eclampsia: impact of as-
pirin after first-trimester screening. Ultrasound Obstet Gynecol.
2015;46(4):419–23. doi: http://dx.doi.org/10.1002/uog.14819. PubMed.
25 Tranquilli AL, Dekker G, Magee L, Roberts J, Sibai BM, Steyn W, et al.
The classification, diagnosis and management of the hypertensive disor-
ders of pregnancy: A revised statement from the ISSHP. Pregnancy Hy-
pertens. 2014;4(2):97–104. PubMed.
26 Purde MT, Baumann M, Wiedemann U, Nydegger UE, Risch L, Surbek
D, et al. Incidence of preeclampsia in pregnant Swiss women. Swiss
Med Wkly. 2015;145:w14175. PubMed.
27 Wu P, van den Berg C, Alfirevic Z, O’Brien S, Röthlisberger M, Baker
PN, et al. Early pregnancy biomarkers in preeclampsia: a systematic re-
view and meta-analysis. Int J Mol Sci. 2015;16(9):23035–56. doi:
http://dx.doi.org/10.3390/ijms160923035. PubMed.
28 Baumann MU, Bersinger NA, Surbek DV. Serum markers for predicting
pre-eclampsia. Mol Aspects Med. 2007;28(2):227–44. doi:
http://dx.doi.org/10.1016/j.mam.2007.04.002. PubMed.
29 Crovetto F, Figueras F, Triunfo S, Crispi F, Rodriguez-Sureda V,
Dominguez C, et al. First trimester screening for early and late
preeclampsia based on maternal characteristics, biophysical parameters,
and angiogenic factors. Prenat Diagn. 2015;35(2):183–91. doi:
http://dx.doi.org/10.1002/pd.4519. PubMed.
30 Ridding G, Schluter PJ, Hyett JA, McLennan AC. Influence of sampling
site on uterine artery Doppler indices at 11-13+6 weeks gestation. Fetal
Diagn Ther. 2015;37(4):310–5. doi: http://dx.doi.org/10.1159/
000366060. PubMed.
31 Ridding G, Hyett JA, Sahota D, McLennan AC. Assessing quality stan-
dards in measurement of uterine artery pulsatility index at 11 to 13 + 6
weeks’ gestation. Ultrasound Obstet Gynecol. 2015;46(3):299–305. doi:
http://dx.doi.org/10.1002/uog.14732. PubMed.
32 Mone F, Mulcahy C, McParland P, McAuliffe FM. Should we recom-
mend universal aspirin for all pregnant women? Am J Obstet Gynecol.
2017;216(2):141.e1–5. PubMed.
33 Xu TT, Zhou F, Deng CY, Huang GQ, Li JK, Wang XD. Low-dose as-
pirin for preventing preeclampsia and its complications: a meta-analysis.
J Clin Hypertens (Greenwich). 2015;17(7):567–73. doi:
http://dx.doi.org/10.1111/jch.12541. PubMed.
34 Elwood PC, Morgan G, Galante J, Chia JW, Dolwani S, Graziano JM, et
al. Systematic review and meta-analysis of randomized trials to ascertain
fatal gastrointestinal bleeding events attributable to preventive low-dose
aspirin: no evidence of increased risk. PLoS One.
2016;11(11):e0166166. doi: http://dx.doi.org/10.1371/jour-
nal.pone.0166166. PubMed.
35 Cruz-Lemini M, Crispi F, Valenzuela-Alcaraz B, Figueras F, Sitges M,
Bijnens B, et al. Fetal cardiovascular remodeling persists at 6 months in
infants with intrauterine growth restriction. Ultrasound Obstet Gynecol.
2016;48(3):349–56. doi: http://dx.doi.org/10.1002/uog.15767. PubMed.
36 Chen CW, Jaffe IZ, Karumanchi SA. Pre-eclampsia and cardiovascular
disease. Cardiovasc Res. 2014;101(4):579–86. doi: http://dx.doi.org/
10.1093/cvr/cvu018. PubMed.
Original article Swiss Med Wkly. 2017;147:w14498
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 8 of 8
